ARWR - Is Arrowhead Pharmaceuticals a Buy Now?
2023-04-16 05:21:00 ET
Are you looking for stocks that can make dramatic moves in a short amount of time? If so, you'll want to check out Arrowhead Pharmaceuticals (NASDAQ: ARWR) . SVB Securities, a subsidiary of SVB Financial , recently gave the stock an upgrade to outperform and raised its price target.
Arrowhead's new price target of $45 per share suggests the stock can gain around 44% over the next 12 months. Before risking any of your hard-earned money on this stock, though, there are some important risks to understand.
Let's weigh this company's strengths against the challenges it's facing to see whether it's a smart buy now.
For further details see:
Is Arrowhead Pharmaceuticals a Buy Now?